WaveMan
WaveMan · Company
SERA · Sera Prognostics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SERA Sera Prognostics (SERA) Insider Trading, Ownership & Congress Trades

Healthcare Services · Services-medical laboratories · CIK 0001534969
Quote by TradingView
Form 144 · 8
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
12
13F, latest reported quarter

What the filings say about SERA

Insiders, 180 days
-$170.2K net sold
6 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$109.8K
8 notices

Sera Prognostics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, SERA PROGNOSTICS, INC. insiders sold a net $170.2K of stock across 216 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Inglis Tiffany Eul Davis
Chief Medical Officer
SELL
2026-10-13 SECtraded 2026-10-12
8,024
$16.3K
-1.9%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Sep 10, 2026.
  • The trade is 9.6% of the 83,565 shares held after it.
  • No other insider sold within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Inglis Tiffany Eul Davis sold about $16.3K of SERA on Oct 12, 2026; 12 funds added in the latest 13F quarter.
Anderson Dyaarl Lee Jr.
Chief Commercial Officer
SELL
2026-09-11 SECtraded 2026-09-10
1,800
$3.6K
+1.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 11, 2026.
  • The trade is 2.4% of the 76,198 shares held after it.
  • 3 other insiders sold within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Anderson Dyaarl Lee Jr. sold about $3.6K of SERA on Sep 10, 2026; 3 other insiders sold within 30 days and 12 funds added in the latest 13F quarter.
Lindgardt Zhenya
Chief Executive Officer
SELL
2026-09-11 SECtraded 2026-09-10
7,022
$14.0K
+1.5%
Context
  • 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Sep 8, 2026.
  • The trade is 0.8% of the 837,848 shares held after it.
  • 3 other insiders sold within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Lindgardt Zhenya sold about $14.0K of SERA on Sep 10, 2026; 3 other insiders sold within 30 days and 12 funds added in the latest 13F quarter.
Inglis Tiffany Eul Davis
Chief Medical Officer
SELL
2026-09-11 SECtraded 2026-09-10
486
$972
+1.5%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 11, 2026.
  • The trade is 0.5% of the 91,589 shares held after it.
  • 3 other insiders sold within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Inglis Tiffany Eul Davis sold about $972 of SERA on Sep 10, 2026; 3 other insiders sold within 30 days and 12 funds added in the latest 13F quarter.
Jackson Benjamin
General Counsel
SELL
2026-09-11 SECtraded 2026-09-10
2,190
$4.4K
+1.5%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (1 buy, 21 sales), the last on Jun 11, 2026.
  • The trade is 1.4% of the 159,566 shares held after it.
  • 3 other insiders sold within 30 days.
  • 12 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Jackson Benjamin sold about $4.4K of SERA on Sep 10, 2026; 3 other insiders sold within 30 days and 12 funds added in the latest 13F quarter.
216 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 211 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$170.2K over 180 days
-$79.6K over 90 days
more than 68% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
12 funds bought in last quarter
below 90% of Healthcare Services
Revenue
+5.2% year over year
below 65% of Healthcare Services
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
0.8% of the float short (float per yahoo 2026-10-26) · 13.4 days to cover · settled 2026-09-30
below 74% of Healthcare Services
What changed in the last 30 days
Oct 13Officer Inglis Tiffany Eul Davis filed to sell $16.3K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13Chief Medical Officer Inglis Tiffany Eul Davis sold $16.3K (Oct 12)

Watch SERA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-37.0%12M
-51%-28%-6%+16%2025-102025-122026-022026-042026-062026-082026-10 2025-12-02 · Kearney Paul sold $94.7K2025-12-09 · Lindgardt Zhenya sold $85.8K2026-06-09 · Lindgardt Zhenya sold $43.2K2026-03-10 · Lindgardt Zhenya sold $43.0K2026-09-08 · Lindgardt Zhenya sold $40.3K2025-11-10 · Lindgardt Zhenya sold $30.4K2025-11-10 · Boniface John J. sold $20.3K2025-11-10 · Kearney Paul sold $18.5K2025-11-10 · Jackson Benjamin sold $18.5K2025-11-10 · Harrison Robert Gardner sold $17.1K2025-11-10 · Aerts Austin sold $16.6K2026-10-12 · Inglis Tiffany Eul Davis sold $16.3K2025-12-09 · Aerts Austin sold $15.9K2026-06-11 · Lindgardt Zhenya sold $14.0K2026-09-10 · Lindgardt Zhenya sold $14.0K2025-12-10 · Lindgardt Zhenya sold $13.8K2026-03-10 · Aerts Austin sold $11.5K2026-06-09 · Aerts Austin sold $11.3K2026-06-11 · Anderson Dyaarl Lee Jr. sold $9.5K2025-11-26 · Kearney Paul sold $7.0K2026-03-09 · Harrison Robert Gardner sold $6.6K2025-11-04 · Harrison Robert Gardner sold $6.1K2026-03-09 · Jackson Benjamin sold $6.1K2026-03-11 · Lindgardt Zhenya sold $6.1K2025-12-30 · Harrison Robert Gardner sold $6.0K2026-03-09 · Boniface John J. sold $6.0K2026-01-27 · Harrison Robert Gardner sold $5.9K2025-12-02 · Harrison Robert Gardner sold $5.9K2025-12-08 · Lawrence Sandra AJ sold $4.8K2026-02-24 · Harrison Robert Gardner sold $4.7K2025-12-10 · Boniface John J. sold $4.4K2026-09-10 · Jackson Benjamin sold $4.4K2026-06-11 · Jackson Benjamin sold $4.4K2026-06-11 · Aerts Austin sold $4.1K2025-12-10 · Kearney Paul sold $4.0K2026-03-09 · Kearney Paul sold $4.0K2026-09-10 · Anderson Dyaarl Lee Jr. sold $3.6K2026-06-08 · Lawrence Sandra AJ sold $3.4K2026-03-11 · Boniface John J. sold $3.1K2026-03-06 · Lawrence Sandra AJ sold $3.0K2025-12-10 · Jackson Benjamin sold $3.0K2025-12-10 · Aerts Austin sold $2.9K2026-10-13 · Inglis Tiffany Eul Davis filed to sell $16.3K2026-09-11 · Aerts Austin filed to sell $3.0K2026-09-11 · Anderson Dyaarl Lee Jr. filed to sell $3.6K2026-09-11 · Inglis Tiffany Eul Davis filed to sell $9722026-09-11 · Jackson Benjamin filed to sell $4.4K2026-09-11 · Lindgardt Zhenya filed to sell $14.0K2026-09-09 · Aerts Austin filed to sell $27.2K2026-09-09 · Lindgardt Zhenya filed to sell $40.3K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SERA: institutional holders (13F)

13F holdings, latest reported quarter
BAKER BROS. ADVISORS LP
5,498,170 sh
$10.0M
Whetstone Capital Advisors, LLC
3,306,889 sh
$6.0M
Aberdeen Group plc
2,753,525 sh
$5.0M
Vivo Capital, LLC
1,650,440 sh
$3.0M
VANGUARD CAPITAL MANAGEMENT LLC
1,297,792 sh
$2.4M

Congress trades in SERA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SERA planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Inglis Tiffany Eul Davis
Filed 2026-10-13
$16.3K
Aerts Austin
Filed 2026-09-11
$3.0K
Anderson Dyaarl Lee Jr.
Filed 2026-09-11
$3.6K
Inglis Tiffany Eul Davis
Filed 2026-09-11
$972
Jackson Benjamin
Filed 2026-09-11
$4.4K

SERA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$93.0K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$186.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$12.7K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$372.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$692.0K position · as of 2026-06-30
0.0%
JNL/DFA U.S. Small Cap Fund
$6.0K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $170.2K sold by insiders over 180 days, 12 funds added last quarter, $109.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
NTRACSTLPGNYHIMSWGSPRVATDOCAVAHGHADUSBDSXBLLN

SERA financials

Revenue growth
+5.2%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$70.0K
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Free cash flow, TTM
-$28.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-45.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-33.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-49.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-47.3%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$81.0K$77.0K$306.0K$268.0K
Operating income-$36.5M-$36.6M-$39.8M-$45.7M
Net income-$31.9M-$32.9M-$36.2M-$44.2M
EPS (diluted)-0.67-0.99-1.16-1.43
Operating cash flow-$25.6M-$14.2M-$27.2M-$34.6M
Cash$3.9M$4.0M$3.9M$29.9M
SEC XBRL, fiscal years, as known on 2026-10-27

SERA Stock Sonar score 5/7 axes

Find similar shapesCompare

SERA ranks highest on risk and compliance (78th percentile) and growth (35th), and lowest on institutional and government (10th), among Healthcare Services peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
20
Inputs
  • Return on equity-45.0% · 25 pct, sector of 70
  • Return on assets-33.5% · 24 pct, sector of 88
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-49.5% · 12 pct, sector of 68
Growth
35
Inputs
  • Revenue growth, YoY+5.2% · 35 pct, sector of 87
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
33
Inputs
  • Net Form 4 buying (codes P and S), 180d-$170K · 67 pct, sector of 64
  • Insider buyers, 180d0 · 0 pct, sector of 64
Institutional and government
10
Inputs
  • Funds adding, latest quarter12 · 10 pct, sector of 73
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
78
Inputs
  • Short interest, % of float+0.8% · 78 pct, sector of 95
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.7% · 77 pct, sector of 72
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SERA filings, in plain words

Are Sera Prognostics insiders buying or selling SERA?

In the 180 days to 2026-10-27, Sera Prognostics insiders were net sellers, a net $170.2K across purchases and sales reported on Form 4, by 6 sellers.

Are there planned insider sales of SERA?

Yes. 8 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $109.8K of stock; the latest, by Inglis Tiffany Eul Davis, was filed 2026-10-13.

Read the full summary

In the 180 days to 2026-10-27, Sera Prognostics insiders were net sellers of SERA, a net $170.2K across purchases and sales reported on Form 4 by 6 sellers. None of the 14 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 8 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $109.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies